Benzodiazepines (BZDs): Mechanism, Indications, Risks & Alternatives

Benzodiazepines (BZDs) are positive allosteric modulators of the GABA_A receptor — enhancing GABAergic inhibition throughout the CNS.

Mechanism

Bind at α/γ subunit interface → increase Cl⁻ influx frequency → neuronal hyperpolarization → sedation, anxiolysis, muscle relaxant, anticonvulsant, amnestic effects.

Clinical Indications

Indication	Preferred Agents	Duration
Generalized Anxiety Disorder	Alprazolam, clonazepam, lorazepam	Short-term (2–4 wks) while SSRI/SNRI takes effect
Panic Disorder	Clonazepam, alprazolam XR	Short-term bridge
Insomnia	Temazepam, triazolam, estazolam	≤2–4 weeks; CBT-I first-line
Seizure Disorders	Clonazepam, clobazam, diazepam (acute)	Adjunctive; status epilepticus = IV lorazepam/diazepam
Muscle Spasm/Spasticity	Diazepam, clonazepam	Short-term
Alcohol Withdrawal	Diazepam, chlordiazepoxide, lorazepam	Taper over 3–7 days (CIWA-guided)
Procedural Sedation	Midazolam (IV)	Single dose

Key Risks

• Dependence & withdrawal: Physical dependence in days–weeks; withdrawal = anxiety, insomnia, tremor, seizures, delirium. Taper slowly (weeks–months).
• Cognitive impairment: Sedation, anterograde amnesia, falls (elderly), driving impairment.
• Respiratory depression: Additive with opioids, alcohol, other sedatives — black box warning.
• Paradoxical reactions: Agitation, disinhibition, aggression (children, elderly).
• Misuse potential: Schedule IV controlled substances.

First-Line Alternatives

• Anxiety: SSRIs, SNRIs, buspirone, CBT.
• Insomnia: CBT-I, melatonin, ramelteon, suvorexant, low-dose doxepin.
• Seizures: Newer AEDs (levetiracetam, lacosamide, etc.).

Prescribing Principles

1. Shortest duration, lowest effective dose.
2. Avoid in substance use disorder, severe respiratory disease, elderly (Beers criteria).
3. PDMP check; informed consent re: risks.
4. Clear discontinuation plan from outset.